We propose to analyze the kinetics of the main marker of inflammation in GCA in order to understand its links with initial clinical manifestations and the possible appearance of complications and/or relapses.
Early assessment of the rate of CRP normalization would enable us to adapt the therapeutic strategy in order to avoid complications and/or relapses.
Inclusion Criteria:
Exclusion Criteria:
Kim.Ly@chu-limoges.fr05 55 05 05 05
Blood samples for CRP determination
Giant Cell Arteritis and Anakinra Trial
Assessment of Giant Cell Arteritis Medical Practices in France
Giant Cell Arteritis: Comparison Between Two Standardized Corticosteroids Tapering
Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic
Performance of a Fast-track Pathway for Giant Cell Arteritis Diagnosis
Disease Activity Monitoring in Patients With Giant Cell Arteritis Study
Predictive Factors for Treatment Response in Patients With Newly-diagnosed Polymyalgia Rheumatica and Giant Cell Arteritis
Upadacitinib in Giant Cell Arteritis (GCA) With Active Large-vessel Involvement.